TY - JOUR
T1 - 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
AU - Ndumele, Chiadi E.
AU - Rodriguez, Fatima
AU - Dixon, Dave L.
AU - Khan, Sadiya S.
AU - Mukherjee, Debabrata
AU - Bajaj, Mandeep
AU - Bangalore, Sripal
AU - Bozkurt, Biykem
AU - Breathett, Khadijah
AU - Clarke, Shoa L.
AU - de Boer, Ian H.
AU - Ellison, David H.
AU - Evangelista, Lorraine S.
AU - Heffron, Sean P.
AU - Kazi, Dhruv S.
AU - Kulshreshtha, Ambar
AU - Lingvay, Ildiko
AU - Low Wang, Cecilia C.
AU - Mercado, Claudia A.
AU - Morton, John Magaña
AU - Neeland, Ian J.
AU - Pagidipati, Neha
AU - Powell-Wiley, Tiffany M.
AU - Rangaswami, Janani
AU - Rao, Goutham
AU - Reza, Nosheen
AU - Saeed, Anum
AU - St. Peter, Wendy
AU - Starks, J. Bradley
AU - Sterling, Madeline
AU - Talbot, Amy W.
AU - Tran, Andrew H.
AU - Tuttle, Katherine R.
AU - VanWagner, Lisa B.
AU - Vest, Amanda R.
AU - Virani, Salim S.
N1 - Publisher Copyright:
© 2026 by the American College of Cardiology Foundation
PY - 2026/6/9
Y1 - 2026/6/9
N2 - Aim: The “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome” retires, replaces, and expands upon the “2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults.” The primary intended audience for this guideline is clinicians who care for patients across the spectrum of cardiovascular-kidney-metabolic syndrome, an interrelated condition characterized by the interconnections among metabolic risk factors (including obesity and type 2 diabetes), chronic kidney disease, and cardiovascular disease. Methods: A comprehensive literature search was conducted from October 29, 2024, to April 14, 2025, to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human subjects that were published since 2015 in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Structure: The focus of this clinical practice guideline is to create a living, working document that provides current knowledge in the field of cardiovascular-kidney-metabolic syndrome aimed at all practicing cardiologists, endocrinologists, nephrologists, and primary care and specialty clinicians who manage these patients.
AB - Aim: The “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome” retires, replaces, and expands upon the “2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults.” The primary intended audience for this guideline is clinicians who care for patients across the spectrum of cardiovascular-kidney-metabolic syndrome, an interrelated condition characterized by the interconnections among metabolic risk factors (including obesity and type 2 diabetes), chronic kidney disease, and cardiovascular disease. Methods: A comprehensive literature search was conducted from October 29, 2024, to April 14, 2025, to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human subjects that were published since 2015 in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Structure: The focus of this clinical practice guideline is to create a living, working document that provides current knowledge in the field of cardiovascular-kidney-metabolic syndrome aimed at all practicing cardiologists, endocrinologists, nephrologists, and primary care and specialty clinicians who manage these patients.
KW - ACC/AHA clinical practice guideline
KW - MASLD
KW - atherosclerosis
KW - atrial fibrillation
KW - blood pressure/hypertension
KW - cardiovascular disease
KW - cardiovascular-kidney-metabolic
KW - coronary disease
KW - diabetes
KW - diagnosis
KW - heart failure
KW - kidney disease(s), chronic
KW - management, cardiovascular-kidney-metabolic
KW - metabolic syndrome
KW - overweight/obesity
KW - peripheral artery disease
KW - renal insufficiency
KW - risk factors
KW - screenings
KW - secondary prevention
KW - venous thromboembolism
KW - weight loss
UR - https://www.scopus.com/pages/publications/105040779277
U2 - 10.1016/j.jacc.2026.03.056
DO - 10.1016/j.jacc.2026.03.056
M3 - Review article
AN - SCOPUS:105040779277
SN - 0735-1097
VL - 87
SP - e1889-e2007
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 22
ER -